<DOC>
	<DOCNO>NCT01301898</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy GC1111 ( recombinant human iduronate-w-sulfatase ) Hunter Syndrome ( Mucopolysaccharidosis II ) patient</brief_summary>
	<brief_title>To Evaluate Safety Efficacy GC1111 ( Recombinant Human Iduronate-2-sulfatase ) Hunter Syndrome Patients</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>1 . Patients diagnosis MPS II base clinical biochemical criterion 2 . Male , age 6 35 year old 3 . Patients able comply study requirement 4 . Patients give voluntary write consent participate study 5 . Patients acceptable use appropriate method contraception 1 . History tracheostomy bone marrow transplant 2 . Known hypersensitivity idursulfase 3 . Known shock idursulfase 4 . History receive treatment another investigational therapy within past 30 day 5 . History stem cell transplant 6 . Known hypersensitivity component idursulfase 7 . Female</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Hunter syndrome</keyword>
	<keyword>MPS II</keyword>
	<keyword>Idursulfase</keyword>
</DOC>